Filing Flows › 10x Genomics (TXG) › Q4 2025
10x Genomics (TXG) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 13, 2026
10x Genomics (TXG) reported revenue of $166M for the fourth quarter 2025 (Q4 2025), +0.6% from a year earlier and +11% from the quarter before. Operating margin was -11.8%, net loss $16.3M (9.8% of revenue).
10x Genomics, Q4 2025: revenue $166M (+0.6% year over year), operating margin -11.8%, net loss $16.3M, operating cash flow $40.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $166M | +11% | +0.6% |
| Operating profit | −$19.5M | — | — |
| Net earnings | −$16.3M | — | — |
| Operating cash flow | $40.8M | -6% | — |
| Free cash flow | $39.0M | -8% | — |
What changed
Revenue was $166.0M in Q4 2025, up 1% year over year and up 11% from the previous quarter. Consumables was the largest line at 85% of revenue.
Gross margin was 68.1%, up 0.9 points from a year earlier. Operating costs exceeded revenue by $19.5M, an operating margin of -11.8%. Operating expenses fell 18% while revenue rose 1%. The quarter ended with a net loss of $16.3M, narrower than the previous quarter's $27.5M loss. Non-operating items added $4.3M, -29% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $40.8M. Non-cash charges added back $10.1M of depreciation and amortization and $25.2M of share-based compensation. Working capital and other items added $21.7M. Capital expenditures of $1.8M left free cash flow of $39.0M.
Questions
What was 10x Genomics' revenue in the fourth quarter 2025?
10x Genomics (TXG) reported revenue of $166M for the fourth quarter 2025 (Q4 2025), +0.6% from a year earlier and +11% from the quarter before.
Was 10x Genomics profitable in the fourth quarter 2025?
Operating loss was $19.5M (-11.8% of revenue) and net loss $16.3M.
Source: 10x Genomics 10-K on SEC EDGAR.